Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Avid Bioservices Tumbled Today

By Maxx Chatsko - Mar 11, 2020 at 2:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.

What happened

Shares of Avid Bioservices (CDMO -0.76%) fell as much as 34.4% today after the company reported fiscal third-quarter 2020 operating results. The contract development and manufacturing organization (CDMO) encountered problems with a specific piece of equipment, which forced it to discard in-process manufacturing runs and delay parts of its manufacturing schedule. As a result, the business had to significantly reduce fiscal full-year 2020 revenue guidance.

Previously, the company had been expecting annual revenue of $64 million to $67 million. It now expects only $55 million to $59 million in revenue during the current fiscal year, which ends on the last day of April.

As of 1:54 p.m. EDT, the small-cap stock had settled to a 31.4% loss.

An angry fist pounding the table as a declining stock chart displays on a tablet below.

Image source: Getty Images.

So what

Avid Bioservices CEO Rick Hancock said he expected the operational setback would be limited to fiscal 2020. To that point, the company exited January (and its fiscal third quarter of 2020) with a revenue backlog of $58 millon. That marked a 12% increase compared to the fiscal second quarter of 2020. 

That said, investors might need to adopt a more cautious mindset for another quarter or two. Trust and track record are paramount to a CDMO. That's kind of the point. A drug developer relieves itself of all the engineering and regulatory headaches of drug manufacturing by hiring a CDMO. When the CDMO you hired or were thinking of hiring encounters a major operational setback, it doesn't create the best optics or foundation for building long-term trust. 

Then again, biomanufacturing isn't easy -- and the company's customers understand that. That's also kind of the point. If you're a drug developer, then better the CDMO encounter the manufacturing problem than you.

Now what

The recent operational setback isn't ideal, but broader industry headwinds could propel Avid Bioservices past the event relatively quickly.

The company is in the process of upgrading major equipment systems, which should make it a more attractive partner for drug developers. There's also a tidal wave of demand for biologic drug manufacturing capacity coming over the horizon. The U.S. Food and Drug Administration (FDA) estimates there are over 1,000 cell and gene therapy clinical trials underway right now, with an additional 200 expected every year for the foreseeable future. There are also over 550 clinical trials underway involving monoclonal antibodies.

Avid Bioservices seems well-positioned to capture the opportunity, but the latest update is a reminder that even obvious growth opportunities aren't guaranteed. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Avid Bioservices, Inc. Stock Quote
Avid Bioservices, Inc.
CDMO
$15.61 (-0.76%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.